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Different laboratory markers are routinely used in the diagnosis and management of gastrointestinal (GI) disease in dogs. In the
present study, starting from feces from both healthy dogs and dogs suffering from food responsive diarrhea (FRD), we tried to
find proteins differently expressed in the two groups of dogs, by using a proteomic approach. Interestingly, we found that the
immunoglobulin J-chain isoform 1 (species: Canis lupus familiaris) was identified only in diseased dogs (not in healthy). J-chain
combines especially IgA monomers to IgA dimers and plays a crucial role for their secretions intomucosal interface. Being the first
study of that kind in the dog, it is only possible to hypothesize that their presence could be likely due to an increased activation of
the immune system or to a mucosal damage or both in FRD patients. Similarly, it is still impossible to assess whether this protein
could be used as diagnostic/prognostic marker of GI disease; however, this study represents a promising first step toward fecal
proteomics in canine GI disorders.
1. Introduction
Food responsive diarrhea (FRD) is included in the group
of canine chronic enteropathies (CCE) [1] and is considered
as the presence of a gastrointestinal (GI) disease lasting
from more than 3 weeks that clinically improve after the
administration of specific diets (elimination diet) or of diets
containing hydrolyzed proteins [2]. Normally, the diagnosis
is made after a positive response to the dietary trial, and even
if some specific fecal markers have been investigated in dogs
suffering from GI disease (e.g., fecal 𝛼1-proteinase inhibitor,
N-methylhistamine, fecal calprotectin, S100A12, etc.) [3–7], a
fecal proteomic study has never been performed on canine
FRD patients.
Proteomics is the comprehensive study of the proteome
(proteins’ structure, functions, etc.) of a specific environment,
and it is one strategy in a wider “-omic” approach [8, 9]. In
canine medicine, proteomics has been applied to different
biological fluids like serum, urine, cerebrospinal fluid, bron-
choalveolar lavage fluid, ovarian follicular fluid, tears, etc.
[10, 11] and to tissues such as mammary cells, muscles, liver,
etc. [11]. Proteomic analyses have also been performed in
some pathological conditions of the dog such as tumors (e.g.,
mammary gland, cutaneous mast cell tumors, lymphoma,
and prostate), muscular dystrophy, lethal acrodermatitis,
babesiosis, mitral valve disease, obesity-related metabolic
dysfunction, reduced renal function and tubulointerstitial
fibrosis, etc. [11–21].
The aim of the present study was to detect and identify,
by a proteomic approach, for the first time in the dog, most
represented proteins in feces from healthy dogs of different
breeds and in dogs suffering from food responsive diarrhea
and then to compare results between the two groups of
dogs.
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2. Materials and Methods
2.1. Dogs. We investigated the fecal samples of 7 healthy dogs
and of 12 dogs suffering from FRD. Inclusion criteria for
healthy dogs were absence of GI signs or of any other clinical
sign and absence of concomitant diseases + no pre/probiotic
administration + no change in diet, within the last 3 months
(they were all periodically controlled as included in a volun-
teer blood donor program). Among the dogs included in the
control group, there were 2 Golden Retrievers, 1 Dobermann,
1 German Shepherd, 1 mestizo, 1 Pit Bull, and 1 Weimaraner.
Five were females and two males, and the mean age was
7.5 years. Dogs included in the FRD group were presenting
GI signs from more than 3 weeks, and all responded to
dietary changes. Routine laboratory and instrumental (ultra-
sonography and radiology) evaluations were consistent with
diagnosis of FRD in all dogs. Histopathology performed on
endoscopic biopsy samples was, in a major part of enrolled
cases, consistent with lymphocytic-plasmacytic enteritis
(LPE) forms. This histological condition is not specific but
concordant with FRD; indeed food responsive enteropathy
and steroid-responsive enteropathy or inflammatory bowel
disease (IBD) cannot be discriminated based on histopatho-
logical results. With regard to breeds, there were 2 mestizo, 1
Boxer, 1 Bull Terrier, 1 Cavalier King Charles spaniel, 1 French
Bulldog, 1 Golden Retriever, 1 Labrador Retriever, 1 Maltese,
1 Shih-Tzu, 1 Siberian Husky, and 1 Staffordshire Bull Terrier.
Seven were males and five females, and the mean age was 5.3
years. All dogs were regularly dewormed.
2.2. Fecal Samples Preparation and Protein Extraction. Nat-
urally voided fecal samples were collected (with owners’
informed consent) at the time of first diagnosis, immediately
after production, and stored at -20∘C. 2.0 grams of frozen
faces from healthy group and from FRD group have been
separately weighed and resuspended in 3 ml of phosphate
buffered saline (PBS) containing a protease inhibitor cocktail
(Sigma-Aldrich, Saint Louis, MO), diluted 1:100. Both sam-
pleswere separately subjected to agitation through amagnetic
stirrer for 30 min in ice. Subsequently the two mixtures
were centrifuged at10000 xg at 4∘C. After centrifugation, the
two supernatants (from healthy group and from FRD group)
were collected, filtered three times with a filter paper, and
one more time with a 0.22 𝜇m filter (Whatman, Maidstone,
UK). These consecutive filtering steps were performed in
order to eliminate contaminations of proteins deriving from
gut microflora. To the obtained filtered samples, ammonium
sulphate (Sigma-Aldrich, Saint Louis, MO) was slowly added
to each sample to achieve saturation at 90%, in order to con-
centrate proteins. This operation was performed maintaining
the samples on ice and under agitation with a magnetic
stirrer. After 30 min incubation in ice, the samples were
subsequently centrifuged at 10000xg for 30 min at 4∘C. After
centrifugation, the supernatants were discarded and each
pellet was resuspended in 500𝜇l PBS. The two samples were
then dialyzed by ultrafiltration membranes (MWCO 3 kDa,
Spectra/Por, Repligen Corporation, Waltham, MA). After
dialysis the total protein content was determined by the
Bradford method [22].
2.3. Two-Dimensional Polyacrylamide Gel Electrophoresis
(2DE). 2DE experiments were performed in triplicate for
each group of samples. Before 2DE, samples were pro-
cessed as follows: 800 𝜇g of each total fecal protein group
(from healthy group and from FRD group), extract as
described in the previous section, was cleaned by the 2-
D Clean-Up Kit (GE-Healthcare Life Sciences, Uppsala,
Sweden) in order to eliminate contaminants, and then
was dissolved in a 350 𝜇L of rehydration solution (8 M
urea; 2% (w/v) 3-[(3-Cholamidopropyl) dimethylammonio]-
1-propanesulfonate (CHAPS); 65 mM dithiothreitol (DTT);
0.001% (w/v) bromophenol blue; 0.5% (v/v) IPG buffer, pH
range 3-10). The first dimension was performed at a pH
range of 3-10 (Immobiline DryStrip, IPG-strip, length 18
cm, GE-Halthcare) on an IPGphor isoelectric focusing cell
(GE-Healthcare) and run as previously described [23, 24].
The second dimension was performed by a 13% SDS-PAGE
using a Protean II apparatus (Bio-Rad, Hercules, CA, USA)
and run as previously described [23, 24]. At the end of the
electrophoretic run, the gels were recovered, stained with
0.1% Coomassie Brilliant Blue R250, destained, and scanned
at 600 dpi resolution. Image analysis was performed using
the PDQuest software (Version 7.1.1; Bio-Rad Laboratories),
according to the protocols provided by the manufacturer
in order to define spot-intensity calibration, spot detec-
tion, background abstraction, calibration, and calculation of
molecular mass and isoelectric point (pI) [23, 24]. The pIs
were determined using a linear 3-10 distribution, and the
molecularmass determinationwas based on themarkers Bio-
Rad low range (phosphorylase b, 97.4 kDa; bovine serum
albumin, 66.2 kDa; ovalbumin 45.0 kDa; carbonic anhydrase,
31 kDa; soybean trypsin inhibitor, 21.5 kDa; lysozyme, 14.4
kDa). After PDQuest analysis, the spots were manually
excised (1 mm in diameter) and the protein extracted
from the gel following the protocol of Shevchenko and
coworkers [25] and subsequently subjected to LC-MS/MS
analysis.
2.4. Liquid Chromatography-Tandem Mass Spectrometry (LC-
MS/MS) Analysis. After the digestion, the tryptic peptides
were dissolved in 100 𝜇l of 0.1% (v/v) trifluoroacetic acid
and subjected to a reversed phase chromatography (C18
Gemini-NX, 𝜇l particle size, 110 A˚ pore size, 250x4.6 mm,
Phenomenex, Torrance, CA.) connected to a HPLC Agi-
lent Technologies 1100 Series (Agilent Technologies, Santa
Clara, CA.). The column effluent was analyzed by MS
using an electrospray ion trap mass spectrometer (Agilent
Technologies LC/MSD Trap SL) operating in positive ion
mode over the mass range 300-2200 amu (atomic mass
units). MS spray voltage was 3.5 kV and the capillary
temperature was maintained at 300∘C. Obtained spectra
were extracted and analyzed by the MASCOT software
(www.matrixscience.com) and by the SONAR software
(http://hs2.proteome.ca/prowl/knexus.html) with the follow-
ing search parameters: database, NCBInr; taxonomy, Eukary-
ota; enzyme, trypsin; peptide tolerance, 1.2 Da; MS/MS
tolerance, 0.6 Da and allowance of one missed cleavage
[26].
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Figure 1: 2DE map of the feces proteins from healthy dog group and FRD dog group. The experiments were performed in triplicate for the
two samples. Differently expressed protein spots are evidenced in red (see also Table 1 for protein identification). First dimension has been
performed using an immobilized pH 3–10 linear gradient strip whereas the second dimension was a 13% SDS-PAGE. The standards were
Bio-Rad low molecular weight (phosphorylase b, 97.4 kDa; bovine serum albumin, 66.2 kDa; ovalbumin 45.0 kDa; carbonic anhydrase, 31.0
kDa; soybean trypsin inhibitor, 21.5 kDa; lysozyme, 14.4 kDa).
2.5. Statistical Analysis. Data were analyzed by using Graph-
PadPrism 6.01 software. One-way ANOVA with Tukey
correction for multiple comparisons were employed when
three or more groups were compared. Significant differences
between means were indicated when P < 0.05.
3. Results and Discussion
Thanks to the extraction protocol described under the Mate-
rials and Methods section, it was possible to obtain a protein
concentration of 2.68±0.27mg/ml starting from 2 grams of
feces. It is important to underline the great availability of
the starting material (feces), which compensates the low
quantity of proteins that can be extracted from the feces
through this procedure. Furthermore, another important
consideration is that regardless of the consistency of the
starting material, a fixed amount of total proteins (800
𝜇g) on the two-dimensional electrophoresis can be always
loaded.
The protein expression profile of fecal samples of healthy
dogs and of dogs suffering from FRD was examined by
2DE in the pH range 3-10. Figure 1 shows a representation
of the protein spots comparison between the two samples.
PDQuest analysis revealed the presence of 12 spots differen-
tially expressed in the fecal samples of healthy subjects and
in the subjects affected to FRD. Among them, the presence
of the spots K1, L, O1, O2, O3 and O4 were found only
in the feces of dogs suffering from FRD. In Figure 2 is
shown the normalized quantity of each spot, whereas the
experimental pI values and the molecular weights of the
spot proteins, compared with the theoretical values found
by the MASCOT or SONAR software, are shown in Table 1.
Before to perform the spots identification, by LC-MS/MS
in combination with a databases search, the twelve spots
of interest were excised from 2-D gels and digested with
trypsin. The obtained results are shown in Table 1. The
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Figure 2:Quantitative analysis of each spot in the healthy group and
in the FRD group. Data are shown asmean values± SE. ∗∗∗ P<0.005;
∗∗P<0.01; ∗P<0.05.
spots present mainly or only in the feces of healthy dogs
are: spot A (Hemoglobin subunit beta, Bos Taurus) and
spot K (Putative Cytochrome P450, Oryza sativa). The spots
found mainly in the feces of dogs affected to FRD are:
spot I (Hypothetical protein, Streptomyces sp.); spots S and
T (DTW domain-containing protein, Microbulbifer dong-
haiensis and hypothetical proteinU973 01647, Staphylococcus
aureus, respectively). The spots K1 and L are found only
in feces of FRD dogs and correspond respectively to UDP-
N-acetylglucosamine diphosphorylase (Zea mays) and to
isopentenyl-diphosphate delta-isomerase (Streptomyces sp.).
The spot O2 has been identified as the immunoglobulin J-
chain isoform 1 (Canis lupus familiaris), whereas spot O1, O3
and O4 were not identified. The spot U corresponds to the
coproporphyrinogen III oxidase (Pontibacillus chungwhen-
sis).
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Fecal proteome has been investigated in humanmedicine
[27, 28], but to the authors knowledge this is the first time
that it is studied in canine medicine, in patients suffering
from FRD. In human medicine, the study of fecal proteome
is considered to have a potential on diseases like Crohn’s
disease, irritable bowel syndrome, colorectal cancer, etc.
[28], and proteomics, more in general, has been applied
with interesting results and promising perspectives in men
suffering from food allergy [9].
Analyzing proteins from canine feces, the most interest-
ing spotwe foundwas the spotO2, identified as immunoglob-
ulin J-chain isoform 1. The joining (J) chain is expressed
in several tissues, most abundant in gastrointestinal tract
and lymphoid tissues. J-chain combines IgM (pentameric
IgM) and (especially) IgA monomers into the dimeric IgA
molecule (but larger polymers are also possible) and it is
extremely important for its transport across the epithe-
lium into mucosal secretions, mediated by the polymeric
immunoglobulin mediated receptor (pIgR) [29–32]. pIgR
mediates the active transport of bound polymeric Ig from
the basolateral to the apical face of the exocrine epithelial
cells. Therefore J-chain has an important role in the releas-
ing of secretory antibodies to the mucosal interface [30].
Thus, it appears that the J-chain plays a regulatory role in
the IgM pentamer-hexamer biosynthesis. It is interesting
to note that hexameric IgM displays important biological
advantages over pentamers in activation of complement
[33, 34]. The fact that IgA and IgM, devoid of the J-chain,
do not bind secretory component (SC) [35] suggests that
pIgR/SC needs to bind not only to the Fc region of IgA,
but also to the J-chain to form a stable IgA2–SC–J complex.
The local humoral immune response is mainly mediated by
secretory IgA, which plays a major role in protecting the
mucosal surface against the invasion of pathogenic agents.
SC present in the molecules of secretory IgA antibodies
has a double role. First, it enhances the stability of the
antibody by conferring resistance to the proteolytic attack
of bacteria or local proteases [36], and second, it ensures,
through itsmultiple carbohydrate residues, appropriate tissue
localization by anchoring the antibody to mucus lining the
epithelial surface [37]. Because of its crucial role, the J-
chain is well conserved among different species, and the
presence of a homologous peptide has been also found in
the invertebrates. In the absence of J-chain, IgA is secreted
as a monomer, the form most common in the blood. In
humans, J-chain a is a polypeptide of 15 kDa containing
eight cysteine residues of which six are involved in intrachain
disulfide bridges and two in disulfide bridges with the 𝛼 or 𝜇
chains. Furthermore, this polypeptide contains one site of N-
glycosylation [30]. We found this protein to be present only
in FRD patients, and this finding is noticeable considering
that IgA deficiencies have been associated with chronic
enteropathies in the dog [38], but also that no differences
in J-chain encoding mRNA were found between healthy
dogs and patients with chronic diarrhea [31]. Unfortunately,
being the first study of that kind in the dog, it is difficult to
define the reason behind J-chain presence in fecal samples
from FRD dogs (and its absence in healthy controls). We
can only speculate that this presence could be due to the
rupture of mucosal immunocytes, followed the subsequent
release of these polypeptides into the intestinal lumen (and
their retrieval in fecal samples), or if it may represent a
consequence of an increased immune system activation due
to the dysbiosis likely associated with the condition, or even
both. Actually, it is known that, besides B cells, J-chain
expression has been detected in developing lymphocytes [39],
dendritic cells (DCs) [40], and intestinal epithelial cells [41],
none of which express secretory forms of Ig heavy chains.
These studies point to novel, perhaps primordial, functions
for J-chain; in particular J-chain also plays a role in the
reduction of activation of complement. J-chain negative IgM
hexamers are 15-20 times more effective at activating com-
plement than J-chain positive IgM pentamers [29]. A conse-
quence of this lack of complement activation it allows J-chain
positive pIgM to bind antigens, as during intestinal dysbiosis,
without causing excessive damage to enterocytes membranes
through complement activation [42]. Since inflammation is
generally suppressed in the intestinal epithelium, it is possible
that this control somehow contributes to upregulation and
secretion of J-chain.
With regard to the other proteins found in a significantly
different amount in the two groups of dogs (Table 1),
but almost all identified with a low score in MASCOT
database, we believe that if confirmed in their nature
as reported below they can be considered as presumable
contaminants, i.e., spot I and L (species: Streptomyces sp.;
accession number WP 046507073.1; MASCOT database
score: 19 and a.n. WP 073935025.1;MASCOT database score
31, respectively) [43], as coming from feed or soil, i.e.,
spot A (species: Bos Taurus; a.n. gi|27819608; MASCOT
database score 16), K (species: Oryza sativa; a.n. gi|50725157;
SONAR database), K1 (species: Zea mays; a.n. ONM18096.1;
MASCOT database score 18), S (species: Microbulbifer dong-
haiensis; a.n. WP 073272148.1; MASCOT database score 19),
U (species: Pontibacillus chungwhensis; a.n. WP 036785728.1;
MASCOT database score 33) [44, 45], as or being part of
animals’ microflora, i.e., spot ID T (species: Staphylococ-
cus aureus; a.n. EZW68888.1; MASCOT database score 19)
[46].
4. Conclusions
Themost noticeable result of the present study is the finding
of immunoglobulin J-chain isoform 1 in dogs suffering from
FRD and its absence in control dogs. Being the first study of
that kind in the dog it is unfortunately difficult to interpret
these data, but we believe that this is a first important
step in the study of fecal proteome in dogs suffering from
chronic enteropathies, with possible important perspectives
in diagnosis and monitoring these conditions; especially if
considering the ease in obtaining samples to be analyzed.
Certainly, the present results need to be confirmed by further
studies and also it is important to underline that once
identified biomarker/s by the 2DE analysis it would be
desirable to develop a faster and simpler technique to allow
its/their identification in the feces sample such as enzymatic
activity or through the use of specific antibodies.
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